Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment

Next Previous
Trial Profile

A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Bronchiectasis; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections; Respiratory tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CONVERT
  • Sponsors Insmed

Most Recent Events

  • 19 May 2021 Results of post hoc analysis assessing NNT and NNH for ALIS+GBT vs GBT alone in patients with treatment refractory Mycobacterium avium Complex Lung Disease, presented at the 117th International Conference of the American Thoracic Society.
  • 19 May 2021 According to an Insmed media release, data from this trial will be presented at he virtual American Thoracic Society (ATS) 2021 International Conference.
  • 19 Apr 2021 Primary endpoint has been met. (Number of Participants Achieving Durable Culture Conversion Through 3 Months Off Treatment in the LAI + MDR Arm Compared to the MDR Arm Alone)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top